/Press Releases

Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections

-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform-San Diego, California, Aug 14, 2019 –Forge Therapeutics, Inc. (Forge), a biotechnology company developing [...]

2019-08-13T20:58:24-07:00August 14th, 2019|

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

  San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea [...]

2019-04-24T09:39:15-07:00April 24th, 2019|

Forge Therapeutics to present at the 18th Annual Needham & Company Healthcare Conference

-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. [...]

2019-03-11T11:07:30-07:00March 11th, 2019|

Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections

  San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that [...]

2019-01-03T10:51:05-07:00January 3rd, 2019|

Forge achieves carb-x milestone to advance its lpxc antibiotic to treat infections caused by the world’s deadliest ‘superbugs’

-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San Diego, California, August 1, 2018 – Forge Therapeutics, [...]

2018-07-31T23:33:37-07:00August 1st, 2018|

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David [...]

2018-04-09T06:55:22-07:00April 9th, 2018|

Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference

-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, [...]

2018-03-21T09:31:14-07:00March 21st, 2018|

Forge Co-founder Presents New Approaches to Treat Infections at the 255th American Chemical Society National Meeting

San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that Professor [...]

2018-03-16T11:24:49-07:00March 19th, 2018|
Load More Posts